SCHEMBL4066698

SCHEMBL4066698

COc1ccc(-c2cc3ncnc(N(CC4=COCO4)Cc4ccccc4)c3s2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 2/20 0.45
PIK3CA P42336 1/20 0.35
KCNH2 Q12809 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
STK17B O94768 4/20 0.33
EGFR P00533 3/20 0.33
IKBKB O14920 1/20 0.32
RIPK2 O43353 1/20 0.32
KIT P10721 2/20 0.31
NOS1 P29475 2/20 0.31
CSF1R P07333 1/20 0.31
FLT1 P17948 1/20 0.31
CLK1 P49759 1/20 0.31
CLK2 P49760 1/20 0.31
CLK3 P49761 1/20 0.31
DYRK1A Q13627 1/20 0.31
CLK4 Q9HAZ1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4067150 0.90 RAB9A (0.45) MAP3K8NPC1RAB9AKMT2ATDP1
SCHEMBL4069660 0.88 IKBKB (0.41) MAP3K8NPC1RAB9ASTK17BEGFR
SCHEMBL3936370 0.87 EGFR (0.37) MAP3K8NPC1RAB9AKMT2ATDP1
SCHEMBL4066630 0.87 MAP3K8 (0.41) MAP3K8STK17BEGFRIKBKBKIT
SCHEMBL3930210 0.87 HSD17B2 (0.41) MAP3K8NPC1RAB9AKMT2ATDP1
SCHEMBL3928357 0.87 EGFR (0.44) MAP3K8NPC1RAB9AKMT2ATDP1
SCHEMBL3931349 0.86 STK17B (0.47) MAP3K8NPC1RAB9AKMT2ATDP1
SCHEMBL3938279 0.85 FLT1 (0.46) MAP3K8KMT2ATDP1STK17BEGFR
SCHEMBL4064216 0.85 STK17B (0.41) MAP3K8NPC1RAB9AKMT2ATDP1
SCHEMBL4068418 0.85 KIT (0.43) MAP3K8NPC1RAB9ASTK17BEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 MAP3K8 1493/4885PIK3CA 1979/4885KCNH2 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.